Immigrants with legal status at risk of being dropped from Medicaid
Tap title to read story
0:00 / 0:55
JQJO — Latest news · Page 182
The era of male birth control may be nearing
Tap title to read story
0:00 / 0:54
Carnegie Mellon nets $3 billion gift, most ever given to a university
Tap title to read story
0:00 / 0:54
Ken Paxton’s Christian identity politics obscure a history of scandal
Tap title to read story
0:00 / 0:57
As AI images become common, the threat to elections draws alarm: ‘How will voters know what’s true?’
Tap title to read story
0:00 / 1:03
A ‘freaked out’ US food industry is hitting back at Maha – with social media influencers
Tap title to read story
0:00 / 0:56
Advertise here
From mass raids to quiet crackdown: a timeline of Trump’s strategic ICE pivot
Tap title to read story
0:00 / 0:59
Celine Dion brings down the curtain on L'Oreal Paris runway show
Tap title to read story
0:00 / 0:52
Florence Pugh says 'East of Eden' series finds humanity in Steinbeck's 'monster', Cathy
Tap title to read story
0:00 / 0:56
Varda raises $250 million at $1.6 billion valuation to scale orbital drug manufacturing
Tap title to read story
In-space manufacturing startup Varda Space has closed a two-hundred-fifty-million-dollar Series D funding round at a one-point-six-billion-dollar valuation, as announced by the company. Led by Lux Capital and Natural Capital, the latest financing brings Varda's total capital raised to five-hundred-ninety-eight million dollars since its founding in 2021. Based in El Segundo, California, Varda develops uncrewed space capsules designed to function as microgravity orbital laboratories for pharmaceutical development and commercial material processing. The company has deployed six missions to orbit using its W-Series capsules, with five successfully returning to Earth. Varda plans to launch two capsules simultaneously on an upcoming SpaceX Falcon 9 rideshare mission, carrying hypersonic research payloads for the Pentagon and commercial clients. While about seventy percent of current payload customers are government-related, the firm aims to transition toward commercial pharmaceutical production, targeting human clinical trials of space-manufactured formulations near the end of the decade.
0:00 / 0:56